Clinical trials: Advanced Non Small Cell Lung Cancer (NSCLC)
- Condition Advanced Non Small Cell Lung Cancer (NSCLC)
- Funder type Industry (pharma, biotech, devices)
Carcinoma, Non-Small-Cell Lung
Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC
To assess the efficacy and safety of PF-3512676 administered in combination with gemcitabine/cisplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to…
- Trial name
- NCT00254904
- Testing
- Cisplatin, Gemcitabine, PF-3512676
- Where
- 120 sites in United States, Austria and 22 more
- Volunteers
- 839 people
- Sponsor
- Pfizer
Advanced or Metastatic Solid Tumors, Ovarian Cancer
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC762, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Non-small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT04875806
- Testing
- NC762
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- NextCure, Inc.
HER2 Mutation-Related Tumors, HER2
A Phase 1/1b Study of IAM1363 in HER2 Cancers
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
- Conditions
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
- Trial name
- NCT06253871
- Testing
- IAM1363
- Where
- 53 sites in United States, France and 6 more
- Volunteers
- 383 people
- Sponsor
- Iambic Therapeutics, Inc
Solid Tumor
A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and…
- Trial name
- NCT07003321
- Testing
- HRS-4508 tablet
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Pancreatic Cancer, NSCLC, Metastatic
Patient Reported Outcomes Registry in Patient With Cancer Cachexia
Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.
- Trial name
- PROXie (NCT02983500)
- Where
- Germany
- Volunteers
- 253 people
- Sponsor
- iOMEDICO AG
Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer.
- Trial name
- NCT04974957
- Testing
- SHR-1701；BP102
- Volunteers
- 71 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-Small-Cell Lung Cancer
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease…
- Trial name
- NCT00085813
- Testing
- Ispinesib
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.
- Conditions
- Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
- Trial name
- NCT07145255
- Testing
- ADC
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- MBrace Therapeutics
NSCLC, Non Small Cell Lung Cancer
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of Erlotinib (Tarceva®) in combination with OSI-906 in Patients with Advanced non-small cell lung cancer (NSCLC) with Activating Mutations of the…
- Trial name
- NCT01221077
- Testing
- OSI-906, Erlotinib
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 88 people
- Sponsor
- Astellas Pharma Inc
Locally Advanced or Metastatic NSCLC
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.
- Trial name
- PISCES (NCT04207775)
- Where
- 16 sites in China
- Volunteers
- 300 people
- Sponsor
- AstraZeneca
Nonsmall Cell Lung Cancer
Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer
This study will treat patients with advanced NSCLC who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may…
- Trial name
- JACKPOT1 (NCT03450330)
- Testing
- AZD4205
- Where
- 4 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Dizal Pharmaceuticals
Solid Tumor, Adult, Refractory Cancer
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT05669430
- Testing
- GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]
- Where
- 13 sites in United States
- Volunteers
- 365 people
- Sponsor
- GV20 Therapeutics
Colorectal Cancer, Non-Small Cell Lung Cancer
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
The main purpose of the study is to evaluate the safety of GDC-1971 in combination with either osimertinib or cetuximab. The study consists of a dose-finding stage followed by an expansion stage.
- Trial name
- NCT05954871
- Testing
- GDC-1971, Osimertinib, Cetuximab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 10 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
- Conditions
- Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT04374877
- Testing
- CHS-388, Pembrolizumab, Toripalimab
- Where
- 23 sites in United States, Singapore and 1 more
- Volunteers
- 145 people
- Sponsor
- Coherus Oncology, Inc.
Non-Small Cell Lung Cancer (NSCLC)
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study treatment (capmatinib), which already shows efficacy and safety in non-Chinese patients, could help Chinese patients with controlling their lung cancer in a safe way.
- Trial name
- GeoMETry-C (NCT04677595)
- Testing
- Capmatinib
- Where
- 17 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors Cancer
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or…
- Trial name
- NCT03071757
- Testing
- ABBV-368, ABBV-181
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Breast Cancer, Head and Neck Squamous Cell Carcinoma
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers
Many patients have cancers that have increased activity of a protein called STAT3 that contributes critically to the development and growth of their cancer.
- Conditions
- Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer
- Trial name
- NCT03195699
- Testing
- TTI-101
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Tvardi Therapeutics, Incorporated
Advanced/Metastatic Non-Small Cell Lung Cancer
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III…
- Trial name
- NCT00723957
- Testing
- Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6)
- Where
- 33 sites in United States, Argentina and 8 more
- Volunteers
- 260 people
- Sponsor
- R-Pharm
Non Small Cell Lung Cancer, Colorectal Cancer
A Study of Personalized Neoantigen Cancer Vaccines
The purpose of this study is 1) to evaluate the feasibility of manufacturing a patient-specific neoantigen cancer vaccine, which involves predicting the patient's neoantigens and generating a vaccine that encodes the predicted…
- Conditions
- Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT03794128
- Testing
- Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing)
- Where
- 5 sites in United States
- Volunteers
- 93 people
- Sponsor
- Gritstone bio, Inc.
Non Small Cell Lung Cancer
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and…
- Trial name
- NCT01121575
- Testing
- PF-02341066, PF-00299804
- Where
- 10 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.